2 Houston health innovation leaders award grants to cancer-fighting researchers

dream team

The Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants. Photo via Rice.edu

Five cancer-fighting research projects were named inaugural recipients of a new grant program founded by two Houston institutions.

Last summer, Rice University and The University of Texas MD Anderson Cancer Center announced they were teaming up to form the new Cancer Bioengineering Collaborative. The shared initiative, created to form innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment, recently launched with an event at the TMC3 Collaborative Building in Helix Park.

At the gathering, the Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants.

“Enhancing CAR-T immunotherapy via precision CRISPR/Cas-based epigenome engineering of high value therapeutic gene targets,” led by Isaac Hilton, associate professor of biosciences and bioengineering at Rice and a Cancer Research and Prevention Institute of Texas (CPRIT) scholar; and Michael Green, associate professor of lymphoma/myeloma at MD Anderson.
“Nanocluster and KRAS inhibitor-based combination therapy for pancreatic ductal adenocarcinoma,” led by Linlin Zhang, assistant research professor of bioengineering at Rice; and Haoqiang Ying, associate professor of molecular and cellular oncology at MD Anderson.
“Engineering tumor-infiltrating fusobacteriumas a microbial cancer therapy,” led by Jeffrey Tabor, professor of bioengineering at Rice; and Christopher Johnston, associate professor of genomic medicine and director of microbial genomics within the Platform for Innovative Microbiome and Translational Research at MD Anderson.
“Preclinical study of nanoscale TRAIL liposomes as a neoadjuvant therapy for colorectal cancer liver metastasis,” led by Michael King, the E.D. Butcher Professor of Bioengineering at Rice, CPRIT scholar and special adviser to the provost on life science collaborations with the Texas Medical Center; and Xiling Shen, professor of gastrointestinal medical oncology at MD Anderson.
“Deciphering molecular mechanisms of cellular plasticity in MDS progression,” led by Ankit Patel, assistant professor of electrical and computer engineering at Rice and of neuroscience at Baylor College of Medicine; and Pavan Bachireddy, assistant professor of hematopoietic biology and malignancy and lymphoma/myeloma at MD Anderson.

The event was a who’s who of Houston-based cancer specialists. Speakers included our city’s favorite Nobel laureate, Jim Allison, director of the James P. Allison Institute, as well as MD Anderson’s vice president of research, Eyal Gottlieb. Attendees were welcomed by the leaders of the initiative, Rice’s Gang Bao and MD Anderson’s Jeffrey Molldrem.

“This collaborative initiative builds on the strong foundation of our existing relationship, combining Rice’s expertise in bioengineering, artificial intelligence and nanotechnology with MD Anderson’s unmatched insights in cancer care and research,” Rice’s president Reginald DesRoches says at the event. “This is a momentous occasion to advance cancer research and treatment with the innovative fusion of engineering and medicine.”

The collaboration is part of Rice’s 10-year strategic plan for leadership in health innovation, called “Momentous: Personalized Scale for Global Impact.” Its goals include a commitment to responsible use of cutting-edge AI.

“As both institutions continue to make breakthroughs every day, we hope this collaborative will enable us to tackle the complex challenges of cancer care and treatment more effectively, ultimately improving the lives of patients here in Houston and beyond," Carin Hagberg, senior vice president and chief academic officer at MD Anderson, adds. "Whether our researchers are working on the South Campus or within the hedges of Rice, this collaborative will strengthen each other’s efforts and push the boundaries of what is possible in cancer.”

From Your Site Articles

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

Rice University's SynthX Center, a collaborative lab focused on cancer treatments, named its inaugural seed grant recipients. Photo via Getty Images

3 Houston cancer-focused research projects receive seed grants from new innovative initiative

funding the future

Three groundbreaking projects have just received seed grants from a new Houston-based source.

This spring, Rice University launched its Synthesis X Center with the goal of fostering the growth of cancer technologies and medications. Now, the SynthX, as it is known, and Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center have announced joint awards of grants to promising teams, all of which have principals at either Rice or Baylor.

The teams include:

A project from Drs. Pabel Miah of Baylor and Lei Li of Rice that involves the development and optimization of high-resolution imaging technology that’s intended for use in removing breast cancer from patients. The researchers combine ultrasound with photoacoustic technology to produce real-time imaging that allows surgeons to spot hard-to-locate tumors. This could reduce or eliminate tumor localization procedures which are invasive and costly.
A leukemia treatment profiting from molecular jackhammers, a type of molecule invented in the Rice University lab of Dr. James Tour. He’s joined in the project by Drs. Xin Li and Yongcheng Song, both of Baylor. Molecular jackhammers vibrate more than a trillion times per second when activated by a specific light frequency. Doing this can kill nearby cancer cells. The new treatment is intended to disrupt the activity of a transcription protein called ENL that helps fuel the growth of leukemia cells in several acute forms of the disease.
A project that could discover how to inspire cancer cells to kill themselves, using a cancer-associated enzyme called lysine demethylase 4A. Baylor’s Dr. Ruhee Dere and Rice’s Dr. Anna Karin-Gustavsson are studying the KDM4A with the process of apoptosis, or programmed cell death, in mind for the aberrant cells.

The seed grants are managed by Rice’s office for Educational and Research Initiatives for Collaborative Health (ENRICH). Each of the three grants is intended to last two years and includes funds of up to $80,000.

The goal is to allow research teams to collect preliminary data that can be used to apply for more substantial grants from bodies like the Cancer Prevention and Research Institute of Texas (CPRIT) or the National Institute of Health (NIH).

Three quarters of the funds will be provided in the first year. Teams that produce grant submissions with multiple principal investigators in that first year will be eligible to collect the additional quarter.

Here's what Houston organizations are benefitting from the latest CPRIT funding announcement. Photo via Getty Images

Houston organizations snag chunk of recently announced $49M cancer research grant funding

show me the money

Houston’s Baylor College of Medicine is beefing up its team of cancer researchers.

The college just received $6 million from the state agency Cancer Prevention and Research Institute of Texas (CPRIT) to recruit three cancer researchers: Graham Erwin, Michael Robertson and Dr. Varun Venkataramani. Each researcher is getting $2 million.

In addition, the University of Texas MD Anderson Cancer Center snagged a $2 million CPRIT grant to recruit Simon Eschweiler.

In all, CPRIT recently announced $49 million in cancer research and prevention grants, including nearly $24 million for recruitment of cancer researchers.

Here’s a rundown of the recruitment grants awarded in Houston:

Graham Erwin. Erwin is a postdoctoral fellow at Stanford University’s Stanford Cancer Institute. He’s a biologist who specializes in DNA sequencing related to the development of cancer therapeutics and diagnostics.
Michael Robertson. Robertson also is a postdoctoral fellow at Stanford. He focuses on molecular and cellular physiology at Stanford’s medical school.
Dr. Varun Venkataramani. Venkataramani, a neuroscientist, is a brain tumor researcher at University Hospital Heidelberg, one of the largest hospitals in Germany.
Simon Eschweiler. Eschweiler is a research assistant professor at Southern California’s La Jolla Institute for Immunology. He specializes in immunotherapy for cancer patients.

Aside from the recruitment grants, three institutions in the Houston area received nearly $6 million in funding for cancer treatment and prevention programs. Here’s an overview of those grants:

Almost $2.5 million for expansion of a program at the University of Texas Medical Branch at Galveston that supplies HPV vaccinations for new mothers.
Nearly $2.5 million for an MD Anderson program that promotes physical activity for cancer survivors.
Almost $500,000 for an MD Anderson program to increase treatment of tobacco users who are participating in opioid treatment programs.
Nearly $500,000 for a University of Houston program designed to help LGBTQ+ Texans lead tobacco-free lives.

“From new research programs, recruitment of preeminent scientists to Texas, pilot studies, new technology, and expanding the reach of successful cancer prevention programs, [the] grants highlight the effect CPRIT is having on not just cancer research and prevention efforts, but on life science infrastructure in Texas,” Wayne Roberts, the organization’s CEO, said in a news release.

The Cancer Prevention and Research Institute of Texas recently announced fresh funding for cancer researchers, and Houston organizations received more than 40 percent of it. Photo via Getty Images

Here's what Houston cancer researchers secured fresh funding from Texas nonprofit

grants incoming

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded around $40 million in grants to cancer researchers and cancer research institutions in the Houston area.

The Houston-area grants represent more than 40 percent of the statewide grants recently approved by Austin-based CPRIT.

The largest local grant, $6 million, went to Hongfang Liu and the University of Texas Health Science Center at Houston. The grant helped attract Liu to UTHealth Houston. She is a pioneer in biomedical informatics, an emerging field in cancer research.

Liu comes to Houston from the Mayo Clinic. At UTHealth Houston, she will be director of the Center for Translational Artificial Intelligence in Medicine within the School of Biomedical Informatics as well as vice president for learning health systems.

In a news release, Dr. Giuseppe Colasurdo, president of UTHealth Houston, says the recruitment of Lui “will strategically enhance the position of Texas as a national and international leader in data science, artificial intelligence, and informatics applications in the diagnosis, prevention, and treatment of cancer.”

Other CPRIT grant recipients at UTHealth Houston were:

Lara Savas — $2,499,492 for early detection and treatment of breast and cervical cancer among Latinas
Chao Hsing Yeh — $1,046,680 for an acupressure program to help patients manage cancer-related pain
Belinda Reininger — $999,254 for a lifestyle intervention program in South Texas
Paula Cuccaro — $449,959 for a targeted approach to boosting HPV vaccinations

What follows is a rundown of other CPRIT grant recipients in the Houston area.

University of Texas MD Anderson Cancer Center

Kenneth Hu — $2 million to recruit him as a first-time, tenure-track faculty member
Dr. Kelly Nelson — $1,998,196 to support a program for early detection of melanoma
Robert Volk — $1,988,211 for a lung cancer screening program
Jian Hu — $1.4 million for research into brain and spinal cord tumors in children
Die Zhang — $1,399,730 for research into cognitive issues caused by radiation treatment
Peng Wei — $1,199,994 for research into the evolution of bladder cancer
Boyi Gan — $1,050,000 for the study of cell death in breast cancer patients
Sue-Hwa Lin — $1,050,000 for a novel immunotherapy to treat the spread of prostate cancer to the bones
Joseph McCarty — $1,050,000 for research into invasive cells in patients with brain or spinal cord tumors
Cullen Taniguchi — $1,049,997 for the study of immune responses related to pancreatic cancer
Dr. Andrea Viale — $1,049,985 for the study of immune responses related to pancreatic cancer
Michael Curran —$1,049,905 for research into blocking DNA damage related to radiation therapy and immunotherapy
Wantong Yao — $1,049,854 for research into a novel therapy for pancreatic cancer
Eleonora Dondossola — $1,025,623 for the study of therapy resistance among certain patients with prostate or kidney cancer
Niki Zacharias Millward — $1,019,997 for the study of a type of kidney cancer that begins in the lining of small tubes inside the organ

Baylor College of Medicine

Xi Chen — $2 million for the study of immunotherapy resistance among some breast cancer patients
Melanie Bernhardt — $1,392,407 for research aimed at improving treatment of acute lymphoblastic leukemia in children
Pavel Sumazin — $1,371,733 for research into hepatocellular carcinoma, the most common type of liver cancer
Maksim Mamonkin — $1,050,000 for improving treatment of T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma

University of Texas Medical Branch at Galveston

Ana Rodriguez — $2,257,898 for an HPV vaccination program in the Rio Grande Valley

Houston Methodist Research Institute

Ewan McRae — $1,999,977 to recruit him to Houston from the United Kingdom’s Cambridge University as an expert in RNA therapeutics

University of Houston

Lorraine Reitzel — $448,726 for lung cancer screening programs

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

Startup funding, sportstech win and more trending innovation news for January

SpaceX loses mega rocket in latest thrilling Starship test flight

Testing

SpaceX launched its Starship rocket on its latest test flight Thursday, but the spacecraft was destroyed following a thrilling booster catch back at the pad.

Elon Musk’s company said Starship broke apart — what it called a “rapid unscheduled disassembly." The spacecraft's six engines appeared to shut down one by one during ascent, with contact lost just 8 1/2 minutes into the flight.

The spacecraft — a new and upgraded model making its debut — was supposed to soar across the Gulf of Mexico from Texas on a near loop around the world similar to previous test flights. SpaceX had packed it with 10 dummy satellites for practice at releasing them.

A minute before the loss, SpaceX used the launch tower's giant mechanical arms to catch the returning booster, a feat achieved only once before. The descending booster hovered over the launch pad before being gripped by the pair of arms dubbed chopsticks.

The thrill of the catch quickly turned into disappointment for not only the company, but the crowds gathered along the southern tip of Texas.

“It was great to see a booster come down, but we are obviously bummed out about [the] ship,” said SpaceX spokesman Dan Huot. “It’s a flight test. It’s an experimental vehicle," he stressed.

The last data received from the spacecraft indicated an altitude of 90 miles and a velocity of 13,245 mph.

Musk said a preliminary analysis suggests leaking fuel may have built up pressure in a cavity above the engine firewall. Fire suppression will be added to the area, with increased venting and double-checking for leaks, he said via X.

The 400-foot rocket had thundered away in late afternoon from Boca Chica Beach near the Mexican border. The late hour ensured a daylight entry halfway around the world in the Indian Ocean. But the shiny retro-looking spacecraft never got nearly that far.

SpaceX had made improvements to the spacecraft for the latest demo and added a fleet of satellite mockups. The test satellites were the same size as SpaceX’s Starlink internet satellites and, like the spacecraft, were meant to be destroyed upon entry.

Musk plans to launch actual Starlinks on Starships before moving on to other satellites and, eventually, crews.

It was the seventh test flight for the world’s biggest and most powerful rocket. NASA has reserved a pair of Starships to land astronauts on the moon later this decade. Musk’s goal is Mars.

Hours earlier in Florida, another billionaire’s rocket company — Jeff Bezos’ Blue Origin — launched the newest supersized rocket, New Glenn. The rocket reached orbit on its first flight, successfully placing an experimental satellite thousands of miles above Earth. But the first-stage booster was destroyed, missing its targeted landing on a floating platform in the Atlantic.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME